Biotech | October 09, 2021
Cyprium Therapeutics and Sentynl, a Zydus subsidiary announce positive data for CUTX-101, CuHis
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Subscribe To Our Newsletter & Stay Updated